SOD1 and amyotrophic lateral sclerosis: They have also shown promise as pharmacodynamic biomarkers, as demonstrated in clinical trials such as VALOR (NCT02623699) and ATLAS (NCT04856982), to evaluate the efficacy and safety of tofersen, an antisense oligonucleotide (ASO) targeting SOD1, in patients with ALS [257, 318].